Abcellera Biologics Inc (ABCL)vsAstraZeneca PLC (AZN)
ABCL
Abcellera Biologics Inc
$5.24
+8.71%
HEALTHCARE · Cap: $1.54B
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 80348% more annual revenue ($60.44B vs $75.13M). AZN leads profitability with a 17.2% profit margin vs -194.9%. AZN earns a higher WallStSmart Score of 62/100 (C+).
ABCL
Hold41
out of 100
Grade: D
AZN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$8.88
Current Price
$5.24
$3.64 discount
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 788.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 45.9% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -14.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 788.0% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ABCL
The primary concerns for ABCL are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ABCL profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
ABCL carries more volatility with a beta of 1.03 — expect wider price swings.
ABCL is growing revenue faster at 788.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 41/100), backed by strong 17.2% margins and 12.5% revenue growth. ABCL offers better value entry with a 64.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?